Novo trades near 11.8 times forward earnings against an 18.6 average, and the piece asks whether that makes it a buying chance or a value trap.
Recap by typeshit. Post by Investseekers on X.
Hanmi set Eppe's first four weeks at 129,800 won ahead of a late-month launch, while Novo seeks Korean insurance coverage for Wegovy in high-risk patients.
About half of Australia's roughly 500,000 GLP-1 users pay privately, A$200 to $700 a month, and the authors argue cost hits those with the most obesity hardest.
Ireland's drug pricing body recommended semaglutide over tirzepatide for cost reasons, and Higgins says it's the right call, with a pun he didn't get to use.
The Turkish professor claims income from weight loss shots now far exceeds total AI revenue, a comparison he makes without sourcing in the snippet.
A Williamsburg shop sells injectable peptide vials for around $95 each, while the FDA has sent warning letters to sellers relying on the same label.
13:47
Ketcham runs through the habits she credits for her 90 pound loss on tirzepatide. Her personal take, not medical advice, so check with a doctor.
Loading…